The data showed the strong anti-tumor and anti-metastatic effects in various epithelial tumor cells by the binding of AMC303 to the extracellular domain of CD44v6. The isoform CD44v6 of the CD44 family of transmembrane glycoproteins has been shown to play a major role in tumor growth and metastasis.
This study has shown that blocking CD44v6, an essential co-receptor for the receptor tyrosine kinases VEGFR-2, c-MET, and RON, interferes with several key steps in tumor progression and metastasis including epithelial-mesenchymal-transition (EMT), cell migration, and invasion.
AMC303, amcure's lead compound, is being developed as a potential treatment for patients with advanced and metastatic epithelial tumors, e.g. pancreatic cancer, head and neck cancer, gastric cancer, colorectal cancer, breast cancer, and lung cancer. It has demonstrated strong effects in various in vitro and in vivo assays.
amcure GmbH, a spin-off from the Karlsruhe Institute of Technology established in 2012, develops peptide-based compounds for the treatment of highly metastatic forms of cancer.
amcure's most advanced development candidate, AMC303, has entered clinical development and has demonstrated in in vivo animal proof-of-concept studies a high efficacy against different types of epithelial cancers. amcure is supported by a grant from the German Federal Ministry of Education and Research.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
D3 Bio announces Series A+ Round completion to advance innovative oncology pipeline
Dizal's sunvozertinib receives US FDA Breakthrough Therapy Designation
Merck launches Phase 3 trial of MK-1084 and KEYTRUDA combination in metastatic NSCLC
Trevi Therapeutics names new vice president of Clinical Development
Personalis validates NeXT Personal test for ultra-sensitive MRD detection
Merck reports lung cancer trial failed to meet endpoints
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib